How to Improve eGFR: Evidence-Based Strategies for Better Kidney Function

What eGFR Measures and Why It Matters

Your eGFR estimates how many milliliters of blood your kidneys filter per minute, adjusted for body surface area. Labs calculate it from serum creatinine (or cystatin C), age, and sex using the CKD-EPI 2021 equation, which removed the race coefficient that older formulas included [1].

An eGFR at or above 90 mL/min/1.73 m² is normal. Values between 60 and 89 sit in stage 2 CKD, though many people in this range have no symptoms. The trouble starts below 60, which marks stage 3 CKD and affects roughly 15% of U.S. adults according to CDC surveillance data [2]. Below 15 signals kidney failure. Every 5-point drop in eGFR below 60 raises cardiovascular mortality risk by about 17%, per a meta-analysis of over 1.1 million participants published in The Lancet [3].

The number matters for medication dosing too. Metformin requires dose reduction below an eGFR of 30 and is contraindicated below 15. GLP-1 receptor agonists like semaglutide remain safe across most CKD stages, but monitoring eGFR dictates when and how prescribers adjust therapy. Knowing your eGFR gives both you and your clinician a single metric to track kidney health over time.

Blood Pressure Control: The Foundation

Lowering blood pressure is the single most impactful modifiable factor for preserving eGFR. That is not a guess. The KDIGO 2024 Clinical Practice Guideline for blood pressure management in CKD recommends a systolic target below 120 mmHg when tolerated, measured by standardized office readings [4].

The SPRINT trial (N=9,361) showed that intensive blood pressure control (systolic target <120 mmHg) reduced the composite kidney outcome by 16% and slowed eGFR decline compared with standard treatment targeting <140 mmHg [5]. In participants who already had an eGFR between 20 and 59 at baseline, the benefit was even more pronounced.

ACE inhibitors and ARBs are the preferred first-line agents. They reduce intraglomerular pressure by dilating the efferent arteriole, which directly protects nephrons. The RENAAL trial demonstrated that losartan reduced the risk of doubling serum creatinine by 25% in patients with type 2 diabetes and nephropathy [6]. A brief note: ACE inhibitors may cause an initial eGFR dip of up to 30%. This is hemodynamic, expected, and not a reason to stop the drug unless the decline exceeds 30% or hyperkalemia develops.

Dr. Rajiv Agarwal, lead author of the FIDELIO-DKD trial, has stated: "The combination of renin-angiotensin blockade with newer agents like finerenone offers additive kidney protection that we did not have a decade ago" [7].

SGLT2 Inhibitors: The Strongest New Evidence

Sodium-glucose co-transporter 2 inhibitors have changed the trajectory of CKD treatment. These drugs, originally developed for type 2 diabetes, protect the kidney through tubuloglomerular feedback, reducing hyperfiltration and intraglomerular pressure independent of glucose lowering.

The DAPA-CKD trial (N=4,304) randomized patients with CKD (eGFR 25 to 75 mL/min/1.73 m²) to dapagliflozin 10 mg or placebo. Results: dapagliflozin reduced the primary composite endpoint (sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death) by 39% (HR 0.61 to 95% CI 0.51 to 0.72) [8]. The annual rate of eGFR decline slowed from −3.53 to −1.98 mL/min/1.73 m² per year, a difference of 1.55 mL/min per year. The benefit held regardless of diabetes status.

EMPA-KIDNEY (N=6,609) confirmed these findings with empagliflozin across an even broader CKD population, showing a 28% reduction in kidney disease progression or cardiovascular death [9]. The FDA approved dapagliflozin for CKD in April 2021, making it the first SGLT2 inhibitor with a standalone kidney indication [10].

A practical point: SGLT2 inhibitors cause an acute eGFR dip of 3 to 5 mL/min in the first two weeks. This reflects reduced hyperfiltration, not kidney damage. It reverses after drug discontinuation and predicts better long-term kidney outcomes. Do not stop the medication for this expected drop.

GLP-1 Receptor Agonists and Kidney Protection

Semaglutide now has direct kidney outcome data. The FLOW trial (N=3,533) randomized patients with type 2 diabetes and CKD (eGFR 25 to 75 mL/min/1.73 m² with albuminuria) to subcutaneous semaglutide 1 mg weekly or placebo. The trial was stopped early for efficacy: semaglutide reduced the primary composite kidney endpoint by 24% (HR 0.76 to 95% CI 0.66 to 0.88) [11].

The annual eGFR slope declined 1.16 mL/min/1.73 m² per year slower in the semaglutide group. This effect appeared additive to background SGLT2 inhibitor use, which about 16% of participants were already taking. Weight loss likely contributes (participants lost a mean of 4.7 kg), but anti-inflammatory and direct tubular effects may also play a role.

For patients on GLP-1 agonists for weight management who also have CKD, this trial provides reassurance that the kidney benefits are real and measurable. Semaglutide does not require dose adjustment until eGFR falls below 15 mL/min/1.73 m², though gastrointestinal side effects may limit tolerability in advanced CKD where nausea from uremia is already present.

Finerenone: The Mineralocorticoid Receptor Antagonist Option

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets kidney inflammation and fibrosis. Unlike spironolactone, it carries a lower risk of gynecomastia and sexual side effects because of its selectivity.

The FIDELIO-DKD trial (N=5,734) showed that finerenone reduced the composite kidney outcome (kidney failure, sustained ≥40% eGFR decline, or renal death) by 18% (HR 0.82 to 95% CI 0.73 to 0.93) in patients with type 2 diabetes and CKD already on maximized ACE inhibitor or ARB therapy [7]. FIGARO-DKD confirmed cardiovascular benefits in earlier-stage CKD [12].

The KDIGO 2024 guideline now recommends finerenone as add-on therapy for patients with type 2 diabetes, an eGFR ≥25, and persistent albuminuria despite ACE/ARB optimization [4]. Potassium monitoring is required: hyperkalemia occurred in 18.3% of finerenone-treated patients in FIDELIO-DKD versus 9.0% on placebo, though discontinuation rates were low (2.3% vs. 0.9%).

Dietary Interventions That Move eGFR

Protein restriction is the most studied dietary intervention for CKD. The MDRD Study (N=840) found that a low-protein diet (0.58 g/kg/day) slowed eGFR decline modestly compared with usual intake (1.3 g/kg/day), particularly in patients with eGFR below 25 [13]. A 2020 Cochrane review of 17 trials concluded that reducing protein intake to 0.6 to 0.8 g/kg/day decreases the risk of reaching end-stage kidney disease by about 32% compared with unrestricted intake [14].

Sodium restriction matters too. The KDIGO guidelines recommend limiting sodium to <2 g/day (<5 g salt) to enhance the efficacy of ACE inhibitors and ARBs [4]. A crossover trial in CKD patients showed that a low-sodium diet reduced proteinuria by 20% on top of ARB therapy, amplifying the kidney-protective effect beyond what the drug achieved alone [15].

The DASH diet pattern (rich in fruits, vegetables, whole grains, and low-fat dairy while limiting red meat and processed food) has been associated with slower eGFR decline in observational cohorts. A prospective analysis of 2,400 participants in the ARIC study found that the highest DASH diet adherence quartile had a 16% lower risk of incident CKD over 24 years compared with the lowest quartile [16].

Potassium intake requires individualization. In stages 1 to 3, plant-based potassium sources appear protective. In stages 4 to 5, potassium restriction becomes necessary as excretory capacity falls.

Glucose Control in Diabetic Kidney Disease

In patients with type 2 diabetes, the relationship between glycemic control and eGFR preservation is well established but nonlinear. The UKPDS showed that lowering HbA1c from a median of 7.9% to 7.0% reduced microvascular complications (including nephropathy) by 25% over 10 years [17]. The ADVANCE trial (N=11,140) demonstrated that intensive glucose control (HbA1c target <6.5%) reduced the incidence of new or worsening nephropathy by 21% compared with standard control [18].

The ADA Standards of Care 2024 recommend an HbA1c target below 7% for most adults with diabetes and CKD, with relaxation to <8% for those with limited life expectancy or high hypoglycemia risk [19]. SGLT2 inhibitors and GLP-1 receptor agonists are preferred glucose-lowering agents in CKD because they offer kidney protection independent of glycemic effects.

Metformin remains a cornerstone but requires eGFR-based dosing: full dose above 45, half dose between 30 and 45, and discontinuation below 30 mL/min/1.73 m². These thresholds shifted upward from the older cutoff of 30 after the FDA revised its guidance in 2016, expanding access for millions of patients with moderate CKD [20].

Exercise and Weight Management

Physical activity improves eGFR through multiple pathways: better blood pressure, improved insulin sensitivity, and reduced systemic inflammation. A systematic review of 12 RCTs (total N=505 CKD patients) found that aerobic exercise three to five times weekly improved eGFR by a mean of 3.2 mL/min/1.73 m² over study periods ranging from 12 to 48 weeks [21].

The type of exercise matters less than consistency. Both aerobic training (walking, cycling) and resistance training showed benefits, though aerobic exercise had slightly larger effect sizes. The KDIGO guideline recommends at least 150 minutes per week of moderate-intensity physical activity for CKD patients, matching the general population recommendation [4].

Obesity independently accelerates eGFR decline through glomerular hyperfiltration: a paradoxically high eGFR in early obesity that masks underlying damage and then drops sharply as nephrons burn out. Weight loss of 5% to 10% of body weight has been associated with reduction in proteinuria and stabilization of eGFR in obese CKD patients. Bariatric surgery studies have shown sustained eGFR improvement of 8 to 12 mL/min at five years in patients with baseline hyperfiltration [22].

Dr. Katherine Tuttle, executive director for research at Providence Health Care, has noted: "We now have four pillars of kidney protection: RAS inhibition, SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone. The question is no longer whether to treat aggressively, but how to layer these therapies safely" [23].

Avoid Nephrotoxic Exposures

Certain medications and substances accelerate eGFR decline. NSAIDs (ibuprofen, naproxen, diclofenac) constrict the afferent arteriole, reducing renal blood flow. Regular NSAID use increases the risk of CKD progression by approximately 32% in patients with existing kidney disease, according to a meta-analysis of 8 observational studies [24]. Short courses for acute pain are generally acceptable, but chronic daily use should be avoided in anyone with an eGFR below 60.

Proton pump inhibitors (PPIs) have been associated with a 20% to 50% increased risk of CKD in large observational studies, though causality remains debated [25]. The AGA recommends limiting PPI use to the lowest effective dose and shortest duration [26].

Other exposures to monitor: IV contrast dye (risk is real but often overstated; adequate hydration mitigates most risk), aminoglycoside antibiotics, lithium, and excessive phosphorus from processed foods. Smoking accelerates eGFR decline by approximately 0.3 mL/min/1.73 m² per year beyond normal aging, and cessation slows that trajectory within 12 months [27].

How Often to Recheck eGFR

Monitoring frequency depends on CKD stage and trajectory. The KDIGO 2024 guidelines recommend the following intervals: at least annually for eGFR 60 to 89 with risk factors, every 6 months for eGFR 30 to 59, and every 3 months for eGFR below 30 [4]. After starting an SGLT2 inhibitor, ACE inhibitor, or ARB, recheck eGFR and potassium at 2 to 4 weeks to confirm the expected hemodynamic dip and rule out acute kidney injury.

Always pair eGFR with a urine albumin-to-creatinine ratio (UACR). An eGFR of 55 with no albuminuria carries a different prognosis than 55 with a UACR of 300 mg/g. The two-dimensional KDIGO heat map uses both values to assign risk categories and guide treatment intensity.

If your eGFR drops by more than 5 mL/min/1.73 m² per year on repeated measurements, refer to nephrology regardless of absolute eGFR value. Rapid decliners benefit from early specialist involvement and multi-drug kidney-protective regimens before reaching dialysis thresholds.